Modality
siRNA
MOA
GLP-1/GIP
Target
CD47
Pathway
Tau
CTCLPBCFSGS
Development Pipeline
Preclinical
~Jul 2011
→ ~Oct 2012
Phase 1
~Jan 2013
→ ~Apr 2014
Phase 2
~Jul 2014
→ ~Oct 2015
Phase 3
~Jan 2016
→ ~Apr 2017
NDA/BLA
Jul 2017
→ Nov 2025
NDA/BLACurrent
NCT06675074
1,453 pts·PBC
2017-07→2025-11·Completed
1,453 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-075mo agoPh3 Readout· PBC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2025-11-07 · 5mo ago
PBC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06675074 | NDA/BLA | PBC | Completed | 1453 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK |